Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022
10 mars 2022 08h05 HE
|
Oncotelic Therapeutics, Inc.
●OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β●OT-101 has completed over six clinical trials against solid tumors with good efficacy●OT-101 is currently undergoing a phase 1b trial in...